LA JOLLA, Calif., Sept. 23 /PRNewswire/ -- Neurome, Inc., a privately held biotechnology company, announced today that it has entered into a research agreement with ImClone Systems Incorporated , in which Neurome will apply its proprietary technologies and expertise in quantitative neuropathology to assist ImClone Systems in the discovery stage investigation of preclinical candidate molecules. Specific financial terms were not disclosed.
The partnership will leverage Neurome's extensive experience in Central Nervous System (CNS) diseases and proprietary technologies (the Neurome Technologies) to provide ImClone Systems with information on the effects of selected preclinical molecules on potential targets in the Central Nervous System.
"We are very pleased to establish a collaboration with ImClone Systems," said Floyd E. Bloom, M.D., Chairman and Founding Chief Executive Officer of Neurome and Chairman of the Department of Neuropharmacology at The Scripps Research Institute. "We believe ImClone Systems' decision to work with Neurome is an important validation of our discovery stage capabilities and proprietary technologies."
Warren Young, Ph.D., President and Chief Technology Officer of Neurome added, "ImClone Systems is a leader in the molecular oncology field, and is now clearly established and positioned to commercialize important human therapeutics. The potential benefits of combining Neurome's proprietary technologies and expertise with ImClone Systems' novel candidates are very exciting."
"ImClone Systems is dedicated to developing and commercializing novel oncology products and these efforts invariably begin with research," said Peter Bohlen, Ph.D., Senior Vice President, Research, of ImClone Systems. "We expect that our work with Neurome will help expedite our efforts in developing certain of our pre-clinical research programs and look forward to a successful collaboration."
Neurome, Inc. is a discovery stage biotechnology company that seeks therapeutic solutions to human neurodegenerative diseases. The company is focusing its efforts on Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis -- neurodegenerative disorders which are currently untreatable and share a number of characteristics which make them particularly amenable to Neurome's expertise and technologies. Since its founding in 2000, the company has developed and optimized proprietary technologies to reveal and quantify gene expression patterns and the resultant morphological details of brain structures in normal and pathological brains with an unprecedented level of sensitivity, specificity and resolution. These unique technologies to measure and assess, at the molecular, cellular and macroscopic levels, neurodegenerative processes at work, are ideally suited to identify the earliest evidence of pathology in animal models of human diseases of the CNS, and to evaluate the comparative effectiveness of candidates for intervention. The company is using these technologies to discover and develop drugs that provide effective treatments for diseases characterized by neurodegeneration. For more information, please visit Neurome's website at http://www.neurome.com/.
Except for historical statements, this press release contains forward-looking statements involving significant risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results to differ materially from Neurome's current expectations. Forward-looking statements include those which express a plan, belief, expectation, estimation, anticipation, intent, contingency, future development or similar expression. Readers are cautioned that forward-looking statements are not guarantees of future performance and that undue reliance should not be placed on such statements. Forward-looking statements speak only as of the dates on which they were made. Neurome undertakes no obligation to publicly update or revise any forward-looking statements or to make any other forward-looking statements, whether as a result of new information, future events or otherwise unless required to do so by the securities laws.